"What started as a soil application for the cannabis industry in 2016 has blossomed into a multi-use soil blend for all types of cultivation, from greenhouse and agricultural applications to cannabis/hemp operations," the Med-X team explains. Med-X has received Patent No. 11,147,266 B2 for its Nature-Cide Insecticidal Soil formulation.
"Med-X’s goal is to provide a pest-free environment without the use of potentially dangerous carcinogenic chemicals that could be harmful in the long term to operators, customers, and the environment. Nature-Cide all-natural pest control solutions are a special blend of green, environmentally friendly, and effective essential oils. The Nature-Cide line of insecticide products has 10 years of research and development behind them, allowing them to be used freely without fear of harming family, pets, or the environment."
Med-X has positioned its Nature-Cide products throughout the United States through national distribution with major distribution venues like Target Specialty Products and Veseris with professional application usage for commercial operations in places such as restaurants, school districts, hospitals, parks & recreation, public transportation, poultry farms, zoos, greenhouse operations, and a gamut of other applications for various industries. Med-X is also positioning its Nature-Cide products into various international regions. The product registration process has begun in places such as Australia and Canada, while orders are being shipped into India, Hong Kong, and Antigua.
Recently, Med-X secured a $100 million capital commitment from GEM Global Yield, LLC SCS (GGY), a Luxembourg-based private alternative investment group. Under the agreement, GGY will provide MED-X with a Share Subscription Facility of up to $100 million for a 36-month term following a public listing of Med-X’s common stock. Management is aspiring to list the Company on the Nasdaq with their reserved symbol “MXRX” to expand their multiple green scene business divisions around the world.
“We are pleased to begin a growth plan with a potential listing to access the capital needed, to not only continue a robust marketing plan for all of our divisions but also to align the company with potential strategic acquisitions to bolster our market capitalization,” said Chief Financial Officer Ronald Tchorzewski.
For more information:
Med-X
8236 Remmet Ave., Canoga Park CA, 91304
818-349-2870
[email protected]
medx-rx.com